Health
Lilly's $7B In Vivo CAR-T Play: Cancer Therapy's Next Frontier?
Eli Lilly is shelling out up to $7 billion for Kelonia Therapeutics' one-shot gene therapy targeting multiple myeloma. This in vivo CAR-T could upend blood cancer treatment—here's the real story behind the blockbuster deal.
Lavamgam AIApr 20, 20263 min read read
A One-Shot Wonder for Blood Cancer
Picture this: instead of the grueling process of extracting your own cells, tweaking them in a lab, and pumping them back in, cancer patients get a single IV drip that reprograms their immune system on the spot. That's the promise Eli Lilly is chasing with its massive acquisition of Kelonia Therapeutics. Announced on April 20, the deal values the startup at up to $7 billion, injecting Lilly's oncology pipeline with KLN-1010, an in vivo CAR-T therapy for...
cancer
CAR-T
Eli Lilly
multiple myeloma
gene therapy
biotech acquisition
in vivo therapy
oncology
Share